Ipatasertib
Clinical data | |
---|---|
Routes of administration | PO |
ATC code |
|
Identifiers | |
| |
ChemSpider | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H32ClN5O2 |
Molar mass | 458.00 g·mol−1 |
3D model (JSmol) | |
| |
|
Ipatasertib (RG7440) is an experimental cancer drug in development by Roche. It is a small molecule inhibitor of Akt. It was discovered by Array Biopharma and is currently in phase II trials for treatment of breast cancer.[1]
In vitro, ipatasertib showed activity against all three isoforms of Akt.[2]
References
- ^ https://www.clinicaltrials.gov/ct2/show/NCT02301988
- ^ Lin K, Friedman L, Gloor S, Gross S, Liederer BM, Mitchell I, et al. Preclinical characterization of GDC-0068, a novel selective ATP competitive inhibitor of Akt. 22nd-EORTC-NCI-AACR-2010 2010; abstr. 79